Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,384.00
Bid: 12,382.00
Ask: 12,384.00
Change: 56.00 (0.45%)
Spread: 2.00 (0.016%)
Open: 12,364.00
High: 12,432.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: FTSE crawling higher as Fed and Budget digested

Thu, 19th Mar 2015 11:48

Come midday on Thursday, stocks were registering slight gains as traders digested the policy announcement issued by the US Federal Reserve overnight, but volatility was still evident in other asset classes such as foreign exchange and commodities.At 12.25 the top flight index was 5.8 points higher at 6,951.01, with some effects from Wednesday's Budget from Chancellor George Osborne also still filtering through.As expected, the US central bank yesterday omitted any reference to being "patient" when starting to tighten interest rates, but the 17 members of the Federal Open Market Committee nearly halved their median projection for the level of the Fed funds rate at year-end 2015 to 0.625%.They also lowered their estimates for the following two years despite having reduced their forecasts for inflation and unemployment. The communiqué from the Fed and follow-up conference from Chair Janet Yellen saw the euro/dollar register its large intraday gain since 2000, no less.On Thursday investors were expected to focus on the summit of European Union heads of government and the news-flow surrounding the negotiations with Greece.That came as the yield on 10-year Greek bonds sprinted 62 basis points higher to 11.72%.Against analysts' predictions Norway's central bank maintained its deposit rate at 1.25%, instead of reducing it by 25 basis points. Nonetheless, the monetary authority clearly signalled that it will soon be lowering its key rate further, analysts at Capital Economics said.Earlier in the day Switzerland's central bank, the SNB, kept its target range for the three-month Libor unchanged, at between -1.25% and -0.25%, as expected. However, the SNB cautioned that it could cut rates further or intervene in foreign exchange markets, if necessary, to curb strength in the swiss franc's value.Next drops after full-year profits UK clothing retailerNext grew its underlying pre-tax profit by 12.5% last year as overall sales rose by 7.2%. The company said its share buyback scheme meant that underlying EPS grew by 14.7% and dividends for the full year will increase by 16.3%, to 150p.Auto Trader Group, the UK car classified ad company on Thursday priced 590m shares at 235p/share in its initial public offering in the London market. The company is raising £437m of net proceeds in the offer with its private equity owner, Apax expected to raise around £926.2m out of the flotation. As of 12:18 the shares were changing hands at 268.75p.Chip designer ARM Holdings's market share in servers may reach 20% by 2020, versus less than 1% at present, the company has reportedly said. The London-listed outfit was scheduled to make a presentation at today's Bank of America Merrill Lynch Technology & Beyond Conference, in Taiwan.Electronics components distributor Premier Farnell reported adjusted profits before tax down 3% to reach £74m in 2014 but maintained its full-year dividend pay-out at 10.4p. That came on the back of a 0.8% fall in full-year revenues to £960.1m. However, the company's operating margins declined by less than forecast by analysts, slipping by 40 basis points, to 9.2%. The analyst consensus was for margins of 9%. Earnings per share (EPS) on an adjusted basis came in at 13.8p, down 3.5% from the prior year but ahead of the 13.5p which analysts had pencilled in.AstraZeneca has signed an agreement with Japanese-headquartered company Daiichi Sankyo to jointly commercialise a new drug called Movantik, an oral treatment for opioid-induced constipation in adults with chronic non-cancer pain. No longer labelled a controlled substance by the US Drug Enforcement Administration, its launch has been scheduled to take place early in April 2015.Savills reported a 21% increase in pre-tax profit to £84.7m, as revenue rose 19% to £1.08bn driven by a 38% increase in transaction advisory revenue, which the company attributed to the performance of the Savills Studley business in the US, strong performances in Asia and the UK and recovery in some European markets.Market MoverstechMARK 3,247.62 -0.06%FTSE 100 6,952.98 +0.11%FTSE 250 17,422.45 +0.34%FTSE 100 - RisersFresnillo (FRES) 676.00p +4.97%Sports Direct International (SPD) 656.50p +2.58%Antofagasta (ANTO) 698.00p +2.42%BHP Billiton (BLT) 1,492.50p +2.37%Randgold Resources Ltd. (RRS) 4,777.00p +2.18%British Land Co (BLND) 867.00p +2.12%Hammerson (HMSO) 687.00p +2.00%Aviva (AV.) 566.00p +1.89%Aberdeen Asset Management (ADN) 478.30p +1.83%GKN (GKN) 375.30p +1.79%FTSE 100 - FallersNext (NXT) 7,350.00p -3.54%British American Tobacco (BATS) 3,672.50p -3.25%Meggitt (MGGT) 580.00p -1.28%Imperial Tobacco Group (IMT) 3,168.00p -1.03%Mondi (MNDI) 1,349.00p -0.81%Pearson (PSON) 1,490.00p -0.80%Unilever (ULVR) 2,903.00p -0.79%HSBC Holdings (HSBA) 574.80p -0.78%Diageo (DGE) 1,939.00p -0.77%Royal Mail (RMG) 445.40p -0.74%FTSE 250 - RisersPremier Oil (PMO) 146.10p +7.58%Soco International (SIA) 157.80p +6.69%Acacia Mining (ACA) 246.50p +4.94%Supergroup (SGP) 916.00p +4.87%Ophir Energy (OPHR) 130.30p +4.41%Countrywide (CWD) 557.50p +4.30%Crest Nicholson Holdings (CRST) 442.60p +4.09%Vedanta Resources (VED) 457.10p +3.91%Centamin (DI) (CEY) 53.50p +3.68%Hunting (HTG) 482.20p +3.37%FTSE 250 - FallersBrit (BRIT) 278.50p -8.60%Lancashire Holdings Limited (LRE) 634.00p -6.70%Jupiter Fund Management (JUP) 408.90p -4.04%Hiscox Ltd (CDI) (HSX) 816.00p -3.77%Jimmy Choo (CHOO) 168.90p -3.49%Premier Farnell (PFL) 184.90p -3.19%Ladbrokes (LAD) 110.80p -2.38%Ted Baker (TED) 2,751.00p -2.34%Serco Group (SRP) 170.80p -2.18%Hellermanntyton Group (HTY) 346.50p -1.84%
More News
27 Jun 2024 13:00

German vaccine panel endorses Astra-Sanofi's RSV shot for infants

FRANKFURT, June 27 (Reuters) - Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infection RSV.

Read more
26 Jun 2024 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar approval in Japan.

Read more
25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

Read more
25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

Read more
25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.

Read more
24 Jun 2024 15:40

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
24 Jun 2024 14:56

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.